<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Treatment recommendations in chronic hepatitis B virus and hepatitis D virus coinfection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>HDV RNA</th>
    <th>ALT</th>
    <th>HBV DNA</th>
    <th>Cirrhosis</th>
    <th>Treatment</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>+</td>
    <td>+</td>
    <td>&lt;2000 IU/mL</td>
    <td>No</td>
    <td>IFN alone</td>
   </tr>
   <tr>
    <td>+</td>
    <td>+</td>
    <td>&gt;2000 IU/mL</td>
    <td>No</td>
    <td>IFN + NA</td>
   </tr>
   <tr>
    <td>+</td>
    <td>+</td>
    <td>&lt;2000 IU/mL</td>
    <td>Yes</td>
    <td>IFN + NA</td>
   </tr>
   <tr>
    <td>+</td>
    <td>+</td>
    <td>&gt;2000 IU/mL</td>
    <td>Yes</td>
    <td>IFN + NA</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tspara0025">
   <p>IFN treatment for 48 weeks: Peg-IFN-α-2a (Pegasys) 180 μg weekly; Peg-IFN-α-2b (PegIntron) 1.5 μg/kg weekly.</p>
  </fn>
  <fn id="tspara0030">
   <p>NA treatment: entecavir (Baraclude) 0.5 to 1 mg daily; tenofovir dipovoxil fumarate (Viread) 300 mg daily; tenofovir alafenamide (Vemlidy) 25 mg daily.</p>
  </fn>
  <fn id="tspara0035">
   <p>
    <italic>Abbreviations:</italic> ALT, alanine transaminase; NA, nucleotide or nucleoside analogue.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
